December 23, 2008 / 1:43 PM / 11 years ago

Glaxo gets aptamer drug options in Archemix deal

* Glaxo can license specified inflammatory drugs

* Pact covers drugs developed using aptamer technology

* Archemix gets $27.5 mln, and up to $200 mln in milestones

* Archemix lined up to merge with NitroMed

LONDON, Dec 23 (Reuters) - GlaxoSmithKline (GSK.L) has secured options to license a number of drug candidates for inflammatory diseases after signing a development pact with U.S.-based Archemix it said on Tuesday.

Privately held Archemix, which is poised to merge with U.S. heart drug company NitroMed NTMD.O, specialises in so-called aptamer technology, which tackles diseases by binding to proteins.

Under the deal with Glaxo, which covers a number of proteins linked to inflammatory diseases such as arthritis and inflammatory bowel disease, Archemix gets a $27.5 million upfront payment and up to $200 million in milestones.

Archemix has agreements with a number of major pharmaceutical companies, including Pfizer (PFE.N) and Eli Lilly (LLY.N), for treatments in a range of disease areas using its aptamer technology. (Reporting by Ben Deighton; Editing by Hans Peters)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below